Back
Sarepta Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
SRPT
Sponsored
BREAKING: Elon Musk's Secret A.I. Project Set to Plunge Millions of Americans Into Poverty
Click here now to prepare yourself for what's around the corner
Buy
53
SRPT
Sarepta Therapeutics
Last Price:
128.73
Seasonality Move:
13.16%
7 Day Trial
ALL ACCESS PASS
$
7
My #1 Coin is...
All the details are on the next page.Sarepta Therapeutics Price Quote
$128.73
-0.04 (1.05%)
(Updated: April 27, 2024 at 6:21 AM ET)
Sarepta Therapeutics Key Stats
Buy
53
Sarepta Therapeutics (SRPT)
is a Buy
Day range:
$125.62 - $131.46
52-week range:
$55.25 - $159.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
9.57
P/B ratio:
14.06%
Volume:
956.8K
Avg. volume:
707.3K
1-year change:
5.31%
Market cap:
$12.1B
Revenue:
$1.2B
EPS:
$-5.83
How Much Does Sarepta Therapeutics Make?
-
How Much Are Sarepta Therapeutics's Sales Annually?
SRPT Revenues are $1.2B -
How Much Profit Does Sarepta Therapeutics's Make A Year?
SRPT net income is -$536M
Is Sarepta Therapeutics Growing As A Company?
-
What Is Sarepta Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.54% -
What Is Sarepta Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Sarepta Therapeutics Stock Price Performance
-
Did Sarepta Therapeutics Stock Go Up Last Month?
Sarepta Therapeutics share price went up by 0.41% last month -
Did SRPT's Share Price Rise Over The Last Year?
SRPT share price rose by 5.31% over the past 1 year
What Is Sarepta Therapeutics 52-Week High & Low?
-
What Is Sarepta Therapeutics’s 52-Week High Share Price?
Sarepta Therapeutics has traded as high as $159.89 over the past 52 weeks -
What Is Sarepta Therapeutics’s 52-Week Low Share Price?
Sarepta Therapeutics has traded as low as $55.25 over the past 52 weeks
Sarepta Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Sarepta Therapeutics?
-
How Much Debt Does Sarepta Therapeutics Have?
Total long term debt quarterly is $1.2B -
How Much Cash Does Sarepta Therapeutics Have?
Cash and short term investments quarterly total is $1.7B -
What Is Sarepta Therapeutics’s Book Value Per Share?
Book value per share is 9.17
Is Sarepta Therapeutics Cash Flow Positive?
-
What Is SRPT Cash Flow From Operations?
Cash flow from operations (TTM) is -$501M -
What Is Sarepta Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $125M -
What Is Sarepta Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$165.8M
Sarepta Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
SRPT return on invested capital is -26.93% -
What Is Sarepta Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -17.08% -
What Is SRPT Return On Equity?
ROE is a measure of profitability and is -77.39%
Sarepta Therapeutics Earnings Date & Stock Price
-
What Is Sarepta Therapeutics's Stock Price Today?
A single share of SRPT can be purchased today for 128.77 -
What Is Sarepta Therapeutics’s Stock Symbol?
Sarepta Therapeutics trades on the nasdaq under the ticker symbol: SRPT -
When Is Sarepta Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Sarepta Therapeutics is scheduled on May 1, 2024 -
When Is SRPT's next ex-dividend date?
Sarepta Therapeutics's next ex-dividend date is April 28, 2024 -
How To Buy Sarepta Therapeutics Stock?
You can buy Sarepta Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Sarepta Therapeutics Competitors
-
Who Are Sarepta Therapeutics's Competitors?
Below is a list of companies who compete with Sarepta Therapeutics or are related in some way:
Sarepta Therapeutics Dividend Yield
Data Unavailable
Sarepta Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 122.73% |
Revenue: | 53.54% | 2.75% |
Analyst Recommendations
Buy Recommendations: | 11 |
---|---|
Hold Recommendations: | 4 |
Sell Recommendations: | 0 |
Price Target: | 164.54 |
Upside from Last Price: | 27.78% |